Holen Sie sich die Stockscreener-App
14.84
0.88%
0.13
Handel nachbörslich:
14.84
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TVTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$14.71
Offen:
$14.71
24-Stunden-Volumen:
1.37M
Relative Volume:
0.79
Marktkapitalisierung:
$1.34B
Einnahmen:
$203.45M
Nettoeinkommen (Verlust:
$-351.45M
KGV:
-3.2615
EPS:
-4.55
Netto-Cashflow:
$-369.41M
1W Leistung:
-0.70%
1M Leistung:
-4.38%
6M Leistung:
-21.77%
1J Leistung:
+83.44%
1-Tages-Spanne:
$14.42
$15.00
1-Wochen-Bereich:
$14.36
$15.27
52-Wochen-Spanne:
$7.72
$25.29
Travere Therapeutics Inc Stock (TVTX) Company Profile
Firmenname
Travere Therapeutics Inc
Sektor
Branche
Telefon
888-969-7879
Adresse
3611 VALLEY CENTRE DR, SAN DIEGO
Vergleichen Sie TVTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
14.84 | 1.34B | 203.45M | -351.45M | -369.41M | -4.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-11 | Bestätigt | Citigroup | Buy |
| 2025-06-11 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-21 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-09 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-03-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-12-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-20 | Eingeleitet | Citigroup | Neutral |
| 2023-09-22 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-05-22 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-05 | Hochstufung | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-21 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Hold |
| 2022-12-05 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-21 | Eingeleitet | Bryan Garnier | Sell |
| 2022-07-14 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-26 | Herabstufung | Wedbush | Outperform → Neutral |
Alle ansehen
Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten
(TVTX) On The My Stocks Page - news.stocktradersdaily.com
Rhumbline Advisers Grows Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
What is HC Wainwright’s Estimate for TVTX Q2 Earnings? - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere ... - Eagle-Tribune
Travere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day - Black Hills Pioneer
HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs - MSN
Leerink Partnrs Has Negative Outlook for TVTX Q4 Earnings - Defense World
Travere Therapeutics’ SWOT analysis: rare disease stock faces regulatory hurdles - Investing.com Canada
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | TVTX Stock News - GuruFocus
Citigroup Issues Pessimistic Forecast for Travere Therapeutics (NASDAQ:TVTX) Stock Price - Defense World
Travere Therapeutics (NASDAQ:TVTX) Stock Rating Upgraded by HC Wainwright - Defense World
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 12, 2025 - BioSpace
10 Best Growth Stocks Under $100 to Buy Now - Insider Monkey
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Travere Therapeutics Inc (TVTX) Has Recovered 53.17% From Its Low: Is This The Beginning Of A Trend? - Stocksregister
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.TVTX - WV News
Travere Therapeutics (TVTX) Price Target Lowered by Citigroup | - GuruFocus
Citi Adjusts Price Target and Maintains Buy Rating on Travere Th - GuruFocus
Travere Therapeutics (TVTX) Price Target Lowered by Citigroup | TVTX Stock News - GuruFocus
Travere Therapeutics (TVTX) Receives Buy Rating from HC Wainwrig - GuruFocus
Travere Therapeutics (TVTX) Receives Buy Rating from HC Wainwright & Co. | TVTX Stock News - GuruFocus
7 Analysts Assess Travere Therapeutics: What You Need To Know - Nasdaq
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference | TVTX Stock News - GuruFocus
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference - Eagle-Tribune
H.C. Wainwright Initiates Coverage on Travere Therapeutics (TVTX) with Optimistic Outlook | TVTX Stock News - GuruFocus
Travere Therapeutics (TVTX) Sees Price Target Adjustment with Ne - GuruFocus
Citi Adjusts Price Target and Maintains Buy Rating on Travere Therapeutics (TVTX) | TVTX Stock News - GuruFocus
Travere Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily
Travere Therapeutics Launches "Play It Forward" Campaign to Cele - GuruFocus
Grammy-Winning Producer Teams Up With Patient Artist for First-Ever FSGS Awareness Campaign - Stock Titan
Travere Therapeutics, Inc. (NASDAQ:TVTX) Stake Boosted by California State Teachers Retirement System - Defense World
Wellington Management Group LLP Invests $583,000 in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Squarepoint Ops LLC Sells 11,006 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Transcript : Travere Therapeutics, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 03 - marketscreener.com
Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
IgA Nephropathy Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approval, Treatment Market, Revenue, Statistics, Therapies, and Companies by DelveInsight - The Globe and Mail
When (TVTX) Moves Investors should Listen - news.stocktradersdaily.com
Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress - BioSpace
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress | TVTX Stock News - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Shareholders to Connect - ACCESS Newswire
2025-06-01 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Shareholders to Reach Out | NDAQ:TVTX | Press Release - Stockhouse
Levi & Korsinsky Launches Fraud Investigation on Behalf of Travere Therapeutics, Inc. (TVTX) Shareholders - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Would Travere Therapeutics (NASDAQ:TVTX) Be Better Off With Less Debt? - simplywall.st
Lost Money on Travere Therapeutics, Inc. (TVTX)? Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Connect - ACCESS Newswire
TVTX Investor Notice: Levi & Korsinsky Investigates Travere Therapeutics, Inc. for Securities Law Violations - Louisiana First News
Finanzdaten der Travere Therapeutics Inc-Aktie (TVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Travere Therapeutics Inc-Aktie (TVTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Dube Eric M | CHIEF EXECUTIVE OFFICER |
May 05 '25 |
Sale |
21.05 |
18,924 |
398,350 |
419,173 |
| Heerma Peter | CHIEF COMMERCIAL OFFICER |
May 05 '25 |
Sale |
21.05 |
1,771 |
37,280 |
128,215 |
| ROTE WILLIAM E. | Chief Research Officer |
May 05 '25 |
Sale |
21.05 |
3,198 |
67,318 |
100,241 |
| REED ELIZABETH E | Chief Legal Officer and GC |
May 05 '25 |
Sale |
21.05 |
4,920 |
103,566 |
89,482 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):